Laura Venegas, Medical Oncologist, Gynecologic Oncology and Drug Development Fellow at University Health Network, shared on LinkedIn:
”Thrilled to share our investigator-initiated proof-of-concept study demonstrating the potential of PKMYT1 inhibition in combination with standard carboplatin and paclitaxel in recurrent gynecologic cancers.
Could the next generation of ADCs combine dual payloads-TOP1 inhibition and PKMYT1 inhibition-to simultaneously induce DNA damage and disable the G2/M checkpoint?
Most importantly, this work would not have been possible without the patients who participated in this study.
A sincere thank you to all my co-authors, collaborators, research teams, and investigators for their dedication and partnership.”
You can also read ‘PARP Inhibitors Combined With Immune Checkpoint Blockade in Gynecologic Cancers‘
